IQV
IQVIA Holdings Inc.Evidence as of 2026-09-03Overview · IQVIA Holdings Inc.
IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-b…
Management team
- Kerri Joseph · SVP of Investment Relation & TreasuryFind on LinkedIn
- Dr. Jeffrey A. Spaeder M.D. · Senior VP, Global Chief Medical & Scientific OfficerFind on LinkedIn
- Mr. Jim Berkshire · Executive Vice President of Global Technology & OperationsFind on LinkedIn
- Ms. Keriann Cherofsky · Senior VP, Corporate Controller & Chief Accounting OfficerFind on LinkedIn
Start your 7-day free trial to see the full management team.
Links open LinkedIn searches, not verified profiles. Team data from our market-data vendor's company profile.
Moneyta sentiment
Where the published evidence leans after the desk debated it — not a rating or a recommendation.
−0.0 on a −2 to +2 scale — was +0.0 before the debate changed the read.
What builds the score
Solid bars are analyst rubric scores; faded bars are computed directly from data. Claims dropped in debate count for nothing; weakened claims count at half weight.
Editor's note
Written after the debate settled — the rest of the page is the evidence behind it.
The evidence balance is Mixed ( -0.0 of a possible +2; confidence high). Reported revenue rose from $ 3,829,000,000 in Q1 2025 (fiscal quarter ended 2025-04-30) to $ 4,151,000,000 in Q1 2026 (fiscal quarter ended 2026-04-30), with sequential increases of $ 188M, $ 83M and $ 51M and a clear narrowing in the dollar and percent step-ups. Operating income moved from $ 496,000,000 in Q1 2025 to a peak of $ 553,000,000 in Q3 2025 (fiscal quarter ended 2025-10-20) and then to $ 514,000,000 in Q1 2026, implying operating margins of roughly 12.96% (Q1 2025), 12.60% (Q2 2025), 13.49% (Q3 2025) and 12.38% (Q1 2026), a modest compression from the Q3 2025 peak.
Shares outstanding have declined steadily from 176,100,000 as of 2025-02-05 (FY 2024) to 166,900,000 as of 2026-04-30, while cash paid for repurchases rose from $ 375,000,000 in Q1 2025 to $ 552,000,000 in Q1 2026. Long-term noncurrent debt shows net increase versus end‑2024, with reported balances ranging from $ 12,838,000,000 (2024-12-31) to $ 13,989,000,000 (2026-03-31). Market signals are mixed: strong short- and medium-term momentum (3‑month +44.9%, 6‑month +48.3%, 12‑1 +25.1%) and a constructive trend state (price +16.3% above the 50‑day SMA, +31.0% above the 200‑day SMA, golden cross age 20 days) sit alongside a material 3‑year max drawdown of -47.1% and above‑average volatility (90‑day annualized +45.2%). Valuation metrics show P/FCF ≈ 28.96, EV/EBITDA ≈ 16.6, P/E TTM ≈ 40.72, and an implied FCF growth rate of about 18.24% under the provided discount/terminal assumptions.
How this note was made
every stage ran before the note was writtenAnalyst desk
Mercer, Oakes, Nash, Ellis, Yates, Talbot and Archer. The desk: named AI agents, not people. Each reads one slice of the evidence and nothing else — no outside knowledge, no browsing — so every finding traces to a source you can open.
Reads the XBRL figures companies file with the SEC — revenue, margins, income, debt and share count, quarter by quarter — and reports which way the trend is running.
Reported revenue was $3,829,000,000 in fiscal Q1 2025 (2025-01-01 to 2025-03-31, 3mo), $4,017,000,000 in fiscal Q2 2025 (2025-04-01 to 2025-06-30, 3mo), $4,100,000,000 in fiscal Q3 2025 (2025-07-01 to 2025-09-30, 3mo) and $4,151,000,000 in fiscal Q1 2026 (2026-01-01 to 2026-03-31, 3mo). These quarter-to-quarter increases were +$188M, +$83M and +$51M respectively, indicating that revenue growth continued but the sequential dollar and percent increases narrowed over these periods.
XBRL companyfacts · 0001478242-25-000087Operating income was $496,000,000 in fiscal Q1 2025 (2025-01-01 to 2025-03-31, 3mo), $506,000,000 in fiscal Q2 2025 (2025-04-01 to 2025-06-30, 3mo), $553,000,000 in fiscal Q3 2025 (2025-07-01 to 2025-09-30, 3mo) and $514,000,000 in fiscal Q1 2026 (2026-01-01 to 2026-03-31, 3mo). Calculated operating margins from those quarters were roughly 12.96% (Q1 2025), 12.60% (Q2 2025), 13.49% (Q3 2025) and 12.38% (fiscal Q1 2026), showing a modest margin compression from the Q3 2025 peak to the latest quarter.
XBRL companyfacts · 0001628280-26-030675Reads the filings themselves, above all the year-over-year diff of Item 1A risk factors: which risks a company added, dropped or quietly reworded since its last annual report.
Nothing in this slice of the evidence rose to a claim — a quiet read, which itself is information.
Which filings the desk reads
The desk reads the annual 10-K in full — its risk factors, and how they changed since last year. Quarterly 10-Qs and event filings (8-Ks, insider Form 4s) are listed for context but not read line by line: the 10-K is where the material risk disclosures live. A brand-new company, or one we have only just begun tracking, may have no annual report on file yet — its risk analysis fills in once that lands.
Reads the signal panel above — momentum, volatility, drawdown, relative strength and beta — and ranks each against the whole research universe rather than judging it in isolation.
Momentum measures are strong: 3-month momentum is +44.9%, 6-month momentum is +48.3%, and the 12-1 momentum is +25.1%; the 6-month momentum ranks in the 93th percentile of the 547-stock research universe and the 12-1 momentum ranks in the 62th percentile.
Moneyta signal set · 2026-09-02weakened in debateTrend-state indicators are constructive: price is +16.3% above the 50-day simple moving average, +31.0% above the 200-day simple moving average, and a golden cross is present with a cross age of 20 days.
Moneyta signal set · 2026-09-02Reads which funds hold the name and at what weight, plus insider Form 4 filings, to show the exposure you may already carry through index funds.
As of 2026-09-02, IQVIA Holdings Inc. was a holding in the IVV ETF with a reported weight of 0.05% of that fund.
ETF constituents · market dataThe membership record for IVV and the 0.05% weight is dated 2026-09-02T13:45:47.228469+00:00 in the provided data.
ETF constituents · market dataReads recent headlines that are genuinely about this company, ignoring rating chatter and market-wide stories. Findings argue in the debate but never move the sentiment score.
Several small institutional 13F filings reported new positions in the company during the second quarter, including Jupiter Topco LLC acquiring 20,686 shares.
News · thelincolnianonline.com · 2026-09-02Additional 13F-based coverage from the same outlet reports other funds adding stakes in the second quarter, including North Star Asset Management Inc. and Redwood Investment Management LLC.
News · thelincolnianonline.com · 2026-08-29Reads parsed Forms 3/4/5 — who bought or sold, at what size, and whether a 10b5-1 plan was involved. Flags clustered open-market officer buying; treats plan sales as routine and never counts a fund or 10%-holder as an officer.
No insider transactions on file in the trailing 180 days.
Reads the implied-expectations math built from the company's own filings (the growth rate today's price would justify, and the multiples beside it) and argues whether the market's bar looks high or low for this business. Never turns the math into a target.
The calculation in the evidence shows an implied free cash flow (FCF) growth rate of 0.1824 (18.24%) that today's price would justify under the stated discount and terminal assumptions.
Valuation inputs · SEC XBRL + stored EOD closePrice-to-FCF (TTM) is 28.96 according to the provided metrics, equivalent to a market price of $263.84 and FCF per share of $9.1107.
Valuation inputs · SEC XBRL + stored EOD closeDebate and risk review
A bull and a bear contest the claims and the chair rules on each; the risk review stress-tests what survived.
A bull and a bear argue the analysts' claims across two rounds, then a chair rules on each one. Only what survives feeds the score — the argument is shown, not hidden, so you can judge the reasoning yourself.
Several pieces of the provided evidence jointly support a favorable read: strong multi-horizon momentum and constructive trend-state indicators (market-0, market-1) coincide with visible shareholder-return activity — declining shares outstanding and materially higher repurchase cash outflow (fundamentals-2, fundamentals-3) — and positive free-cash-flow generation (valuation-4) that underpins an implied FCF growth rate priced into the stock (valuation-0). Institutional 13F additions and positive company publicity around AI/technology awards (news-0, news-1, news-3) add durability to demand signals. These factors together suggest buyer interest, improving technical posture, and management capital allocation aligned with returning cash to shareholders; the valuation metrics show the market is pricing in elevated cash-flow expectations but those are anchored by actual reported FCF and buyback activity.
Chair's verdict, claim by claim
Fragility · computed, not argued
balanced0.33
24 surviving claims rest on 12 distinct sources; the heaviest analyst carries 25% of them, and 96% of what the desk raised survived the debate.
The evidence base is moderately concentrated: 24 surviving claims draw on a dozen distinct sources, with a single analyst responsible for a quarter of the claims and very little attrition during review. That pattern raises caution about overweighting any single viewpoint—survival through debate suggests the claims are resilient to initial challenge, but source concentration and analyst dependence reduce how much confidence a reader should place in them without further independent corroboration.
Peer context · computed, not argued
12-1 momentum ranks 2nd of 6 in Diagnostics & Research (as of 2026-09-02).
6-month relative strength ranks 1st of 6 in Diagnostics & Research (as of 2026-09-02).
90-day volatility ranks 1st of 6 in Diagnostics & Research (as of 2026-09-02).
dividend yield ranks 4th of 6 in Diagnostics & Research (as of 2026-09-02).
Disconfirming evidence · base rates · falsifiers
Context
Outside consensus, and where this name already sits in your own portfolio.
Third-party consensus shown for context. It never enters Moneyta sentiment — when the two diverge, the debate above is where the why lives.
What this was built from
Every figure on this page traces to one of these. The desk reads only what is listed here — no outside knowledge, no browsing — and each card shows who read it and what it contributed to the score.
12 filings· 2 cited
SEC XBRL filings
Quarterly figures as filed with the SEC, read straight from EDGAR's structured data — not retyped or estimated.
Read by Mercer+0.0 to the score
1 signal set
Moneyta signal set
Computed from our own end-of-day price history and ranked against the whole research universe. No AI involved.
Read by Nash−0.1 to the score
1 holdings record
Fund holdings
Which funds hold this name and at what weight, plus insider Form 4 filings.
Read by Ellis+0.0 to the score
8 headlines· 2 cited
News coverage
Recent headlines about this company, rating chatter excluded and nothing published after the report date.
Read by Yatesnothing survived
1 computation
Valuation inputs
TTM cash-flow figures from the company's own XBRL filings, priced with the stored closing price. Implied growth and multiples only; no fair-value dollar figure reaches the desk, by design.
Read by Archercontext only
1 record· 0 cited
Company profile
Sector, industry and company details.
1 record· 0 cited
Analyst consensus
Third-party consensus, shown for context only — it never enters Moneyta sentiment.
Read means we pulled and handed it to an analyst; cited means a claim on this page points at it. Reading twelve quarters to state one trend is normal — the gap is shown rather than hidden.
Written by AI, checked against sources
The analysts, the bull–bear debate and the editor's note are AI agents reading only the evidence listed on this page. They can misread a filing or a headline, which is why every claim cites a source you can open and check yourself. The sentiment score is arithmetic over the claims that survived the debate, not a language model's opinion.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations. Past patterns do not indicate future results.
Get this for the tickers you actually hold
Plus the one thing no sample can show: how each name correlates with your portfolio, and what hides inside your funds.
The full terminal on IQV Gold
Who holds it, who's buying, what the Street thinks: live behind the lock, updated as filings land.
Institutional holders
Net institutional flow, Q/Q
Largest holder position
Insider buys, 90 days
Clustered insider value
Street target range
The real figures are for members. Educational analysis, not advice.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations.